130 related articles for article (PubMed ID: 18064346)
21. [Calcified subcutaneous nodules in patients with chronic renal failure as a result of injections with nadroparin (Fraxiparine)].
Wanic-Kossowska M; Kozioł L; Roszkowiak B; Lacka M; Frankiewicz D; Mandel M
Pol Arch Med Wewn; 1998 May; 99(5):414-6. PubMed ID: 9816892
[TBL] [Abstract][Full Text] [Related]
22. Heparin-induced skin lesions.
Schindewolf M; Lindhoff-Last E; Ludwig RJ; Boehncke WH
Lancet; 2012 Nov; 380(9856):1867-79. PubMed ID: 22642893
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous adverse events associated with heparin.
Maldonado Cid P; Alonso de Celada RM; Noguera Morel L; Feito-Rodríguez M; Gómez-Fernández C; Herranz Pinto P
Clin Exp Dermatol; 2012 Oct; 37(7):707-11. PubMed ID: 22998541
[TBL] [Abstract][Full Text] [Related]
24. [Allergic drug exanthema to heparin. Cutaneous reactions to high molecular and fractionated heparin].
Greiner D; Schöfer H
Hautarzt; 1994 Aug; 45(8):569-72. PubMed ID: 7960760
[TBL] [Abstract][Full Text] [Related]
25. Delayed allergic skin reactions due to subcutaneous heparin-calcium, enoxaparin-sodium, pentosan polysulfate and acute skin lesions from systemic sodium-heparin.
Koch P; Hindi S; Landwehr D
Contact Dermatitis; 1996 Feb; 34(2):156-8. PubMed ID: 8681559
[No Abstract] [Full Text] [Related]
26. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux.
Hohenstein E; Tsakiris D; Bircher AJ
Contact Dermatitis; 2004 Sep; 51(3):149-51. PubMed ID: 15479206
[No Abstract] [Full Text] [Related]
27. Incidence and causes of heparin-induced skin lesions.
Schindewolf M; Schwaner S; Wolter M; Kroll H; Recke A; Kaufmann R; Boehncke WH; Lindhoff-Last E; Ludwig RJ
CMAJ; 2009 Oct; 181(8):477-81. PubMed ID: 19786468
[TBL] [Abstract][Full Text] [Related]
28. [Delayed hypersensitivity to heparins and heparinoids].
Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
[TBL] [Abstract][Full Text] [Related]
29. Fondaparinux.
Tan KT; Lip GY
Curr Pharm Des; 2005; 11(4):415-9. PubMed ID: 15725062
[TBL] [Abstract][Full Text] [Related]
30. Delayed-type hypersensitivity to subcutaneous heparin with tolerance of i.v. administration.
Liew G; Campbell C; Thursby P
ANZ J Surg; 2004 Nov; 74(11):1020-1. PubMed ID: 15550103
[No Abstract] [Full Text] [Related]
31. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
[TBL] [Abstract][Full Text] [Related]
32. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans.
Ludwig RJ; Beier C; Lindhoff-Last E; Kaufmann R; Boehncke WH
Contact Dermatitis; 2003 Sep; 49(3):158-9. PubMed ID: 14678213
[No Abstract] [Full Text] [Related]
33. The complex clinical picture of side effects to anticoagulation.
Trautmann A; Seitz CS
Med Clin North Am; 2010 Jul; 94(4):821-34, xii-iii. PubMed ID: 20609865
[TBL] [Abstract][Full Text] [Related]
34. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
Kalfarentzos F; Stavropoulou F; Yarmenitis S; Kehagias I; Karamesini M; Dimitrakopoulos A; Maniati A
Obes Surg; 2001 Dec; 11(6):670-6. PubMed ID: 11775562
[TBL] [Abstract][Full Text] [Related]
35. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
Gerhardt A; Zotz RB; Stockschlaeder M; Scharf RE
Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521
[No Abstract] [Full Text] [Related]
36. [A study of 19 cases of allergy to heparins with positive skin testing].
Phan C; Vial-Dupuy A; Autegarden JE; Amsler E; Gaouar H; Abuaf N; Pecquet C; Francès C; Soria A
Ann Dermatol Venereol; 2014 Jan; 141(1):23-9. PubMed ID: 24461090
[TBL] [Abstract][Full Text] [Related]
37. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
38. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
[TBL] [Abstract][Full Text] [Related]
39. Delayed-type hypersensitivity to subcutaneous enoxaparin.
Méndez J; Sanchís ME; de la Fuente R; Stolle R; Vega JM; Martínez C; Armentia A; Sánchez P; Fernández A
Allergy; 1998 Oct; 53(10):999-1003. PubMed ID: 9821483
[TBL] [Abstract][Full Text] [Related]
40. Successful use of fondaparinux early after mechanical aortic valve replacement in a patient with a history of heparin-induced thrombocytopenia.
Willenborg KL
Pharmacotherapy; 2014 Jun; 34(6):e55-9. PubMed ID: 24644124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
